Search the Newsreel

Co-Diagnostics outlines FDA dual 510(k) and CLIA waiver submission as cash falls to $3.6M

Earnings Call Insights: Co-Diagnostics (CODX) Q2 2026 MANAGEMENT VIEW * Dwight Egan (Chairman, CEO & President) framed Q2 as “another important step in our transition from platform development toward commercialization,” emphasizing “advancing regulatory milestones, expanding our global commercial opportunities, enhancing our platform capabilities and …

Co-Diagnostics (CODX) posts Q2 loss and flags going concern, raises new equity

Co-Diagnostics (CODX) reported significant losses and minimal revenue for Q2 2026, leading management to flag substantial doubt about its ability to continue as a going concern without additional capital. The company posted a net loss of $6.3 million for the quarter and $15.4 million …

Co-Diagnostics (CODX) Stock Falls on Q2 2026 Earnings

CODX Stock Explodes Over 630% In Six Sessions – Retail Traders Bet The Rally Isn’t Over Yet

Co-Diagnostics (CODX) shares surged by nearly 80% on Tuesday, extending a six-session rally that has seen the stock climb over 630%. This surge is attributed to the company's expanded efforts to develop a PCR test for the Bundibugyo strain of the Ebola virus, amidst …

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Co-Diagnostics, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting revenue of $0.17 million and a net loss of $6.3 million. The company highlighted significant operational progress, including advancing manufacturing in Saudi Arabia, expanding commercial outreach in Europe and …

CODX Q2'26 Earnings: EPS estimate is (3.00) USD

Co-Diagnostics, Inc. (CODX) is scheduled to release its Q2'26 earnings on August 13th, after market close, with an anticipated announcement time of 4:01 PM ET (8:01 PM UTC). Analysts estimate revenue for the quarter to be 132.58 thousand USD and earnings per share (EPS) …

Why Did CODX Stock Nearly Double In Value Today?

Co-Diagnostics (CODX) stock surged 93% after the company announced it completed the assay development strategy for the Bundibugyo strain of the Ebola virus, linked to the ongoing outbreak in the Democratic Republic of Congo and Uganda. The World Health Organization has expressed serious concerns …

Co-Diagnostics (NASDAQ: CODX) sees Jane Street disclose 1.7% equity stake

Jane Street Group, LLC and its subsidiaries, Jane Street Capital, LLC and Jane Street Global Trading, LLC, have disclosed a 1.7% equity stake in Co-Diagnostics, Inc. (NASDAQ: CODX). This ownership amounts to 89,240 shares of common stock, held with shared voting and dispositive power. …

Co-Diagnostics Submits Co-Dx PCR Flu A/B & RSV Test for FDA Clearance

Co-Diagnostics has submitted its Co-Dx PCR Flu A/B & RSV multiplex respiratory test for FDA clearance, including a dual 510(k) premarket notification and a CLIA Waiver by Application. This submission is backed by extensive clinical studies involving over 1,400 patients and an analytical program …

Co-Diagnostics' Test Filing Draws on 1,400 Patients

Co-Diagnostics (Nasdaq: CODX) has submitted a Dual FDA 510(k) premarket notification and a concurrent CLIA Waiver by Application for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test. This test is designed for use on the Co-Dx PCR Pro instrument in decentralized …

Co-Diagnostics submits FDA 510(k) for respiratory test

Co-Diagnostics, Inc. has submitted a Dual 510(k) premarket notification and a concurrent CLIA Waiver by Application to the FDA for its Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test. This submission aims to allow the test to be used in decentralized point-of-care …

Co-Diagnostics (Nasdaq:CODX) - Stock Analysis

Co-Diagnostics, Inc. (Nasdaq:CODX) is a molecular diagnostics company trading significantly below its estimated fair value despite forecasts for substantial revenue growth. The company faces risks such as past shareholder dilution, high share price volatility, and a small market capitalization. Recent developments include submitting FDA …

Weekly Recap: Co-Diagnostics, Inc. Q2 results date and Bundibugyo test

Co-Diagnostics, Inc. (NASDAQ:CODX) is scheduled to report its Q2 2026 financial results on August 13 after market close, followed by an earnings call. The company also announced a proof-of-concept extraction-free test for the Bundibugyo virus, designed for rapid detection during outbreaks.

Co-Diagnostics Announces Second Quarter 2026 Earnings Release Date and Webcast

Co-Diagnostics, Inc. (Nasdaq: CODX) announced that it will release its second quarter 2026 financial results on Thursday, August 13, 2026, after market close. The company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss the …

Co-Diagnostics Raises Capital Through Warrant Inducement Ahead of FDA Review

Co-Diagnostics, which has no FDA-cleared products, raised capital on July 30, 2026, by inducing existing warrant holders to exercise early in exchange for new warrants. This move aims to secure immediate cash without dilutive equity pricing while the company awaits a crucial FDA 510(k) …

Co-Diagnostics Plans Aug. 13 Webcast on Second-Quarter Results

Co-Diagnostics Joint Venture CoSara Initiates Clinical Studies in India for Tuberculosis Test on PCR Platform

Co-Diagnostics, Inc. announced that its joint venture in India, CoSara Diagnostics Pvt. Ltd., has initiated clinical studies for a tuberculosis test on the CoSara PCR Pro instrument. This marks a significant step following the shipment of PCR Pro instruments and MTB test kits to …

CODX | Co-Diagnostics, Inc. Common Stock Executive Compensation

Co-Diagnostics Names New Chief; Co-Dx PCR Is Not Yet for Sale

Co-Diagnostics (Nasdaq: CODX) has appointed Wes Lindsey, PhD, MBA as its new Chief Scientific Officer, leveraging his 20 years of experience in molecular diagnostics to support regulatory submissions for its Co-Dx PCR platform. Despite this strategic leadership addition, the Co-Dx PCR platform, including its …

Co-Diagnostics Appoints Wes Lindsey, PhD, MBA as Chief Scientific Officer

Co-Diagnostics, Inc. has announced the appointment of Wes Lindsey, PhD, MBA, as its new Chief Scientific Officer. Dr. Lindsey brings over 20 years of experience in molecular diagnostics, including leading assay development and R&D teams through numerous FDA 510(k) submissions and CE-marked assays. His …